Track topics on Twitter Track topics that are important to you
Mewburn Ellis LLP are delighted that the acquisition of Spirogen by MedImmune from Auven Therapeutics for $200 million has been successfully concluded. The deal also involved a deferred consideration of up to $240 million. We are proud to have played a key role in this recent acquisition, given our intimate knowledge of their IP portfolio and agreements over their history.Mewburn Ellis has been Spirogen’s sole patent attorney since their foundation in August 2000, having drafted the patent applications which were used in the initial fund raising. With a team led by partner, Robert Watson, we have advised them through taking a product into clinical trials, various fund-raising rounds, deals with Ipsen and Celtic Therapeutics, and their more recent numerous evaluations and collaborations in the Antibody drug conjugate field. We look forward to continuing our relationship with Spirogen in this exciting new phase in their corporate life as antibody drug conjugates comprising Spirogen’s pyrrolobenzodiazepine (PBD) technology enter into clinical trials (e.g. with Seattle Genetics).NEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...